IGF2 and lung carcinoma: For example, using this analysis platform and patient-derived lung cancer cells, we found that activation of the insulin-like growth factor receptor type 1 pathway mediated by insulin-like growth factor 2 autocrine was a common clinically associated mechanism of the acquired resistance to osimertinib[10].